Retrospective analysis reveals high hematologic response rates in relapsed/refractory light-chain amyloidosis after venetoclax treatment, suggesting promising outcomes.
Key Points
Venetoclax treatment yielded a 93% hematologic response rate in relapsed/refractory light-chain amyloidosis patients.
High t(11;14) was linked to 92% CR+VGPR rates compared to 20% for low t(11;14), indicating potential biomarkers for treatment success.
Adverse events were minimal, supporting venetoclax as a promising therapy for relapsed/refractory light-chain amyloidosis.
This analysis indicates a potential new standard in the treatment of relapsed/refractory light-chain amyloidosis, especially for patients with high t(11;14).